High prevalence of hepatitis B and syphilis co-infections among HIV patients initiating antiretroviral therapy in the north-west region of cameroon

International Journal of STD and AIDS

Volumn 23, Issue 6, 2012, Pages 435-438

  Zoufaly, A ^a   Onyoh, E F ^b   Tih, P M ^b   Awasom, C N ^c   Feldt, T ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Cameroon Baptist Convention Health Board ^*  (Germany)

^c Bamenda Regional Hospital   (Germany)

^d BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

Africa; Co infections; HBV; Hepatitis B; HIV; Risk factors; Screening; Syphilis; Treponema pallidum

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE;

ADULT; ARTICLE; CAMEROON; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; FEMALE; FLUORESCENT TREPONEMA ANTIBODY TEST; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; SYPHILIS;

ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; ANTIBODIES, BACTERIAL; CAMEROON; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; COINFECTION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; SYPHILIS;

EID: 84864041797     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011279     Document Type: Article

References (19)

1. UNAIDS Report on the Global AIDS Epidemic 2010. See: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf (last accessed 29 May 2012)
2. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926
3. Livry C, Binquet C, Sgro C, et al. Acute liver enzyme elevations in HIV-1-infected patients. HIV Clin Trials 2003;4:400-410
4. Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003;32:259-267
5. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-1306
6. Zetola NM, Klausner JD. Syphilis and HIV infection: an update. Clin Infect Dis 2007;44:1222-1228
7. Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004;18:2075-2079
8. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 2009;81:406-412
9. Laurent C, Bourgeois A, Mpoudi-Ngole E, et al. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Med 2010;11:85-89
10. Rouet F, Chaix ML, Inwoley A, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004;74:34-40
11. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-1485
12. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. See http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (last accessed 29 May 2012)
13. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351: 1521-1531
14. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117
15. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 18 November 2010
16. WHO. Immunization Profile - Cameroon. 2011. See: http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm (last accessed 25 June 2012)
17. Mbu ER, Kongnyuy EJ, Mbopi-Keou FX, Tonye RN, Nana PN, Leke RJ. Gynaecological morbidity among HIV positive pregnant women in Cameroon. Reprod health 2008;5:3
18. Rydzak CE, Goldie SJ. Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa. Sex Transm Dis 2008;35:775-784
19. Chiaramonte M, Stroffolini T, Ngatchu T, et al. Hepatitis B virus infection in Cameroon: a seroepidemiological survey in city school children. J Med Virol 1991;33:95-99